Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

Judge files lawsuit over husband’s death—alleges heart symptoms were mismanaged
The patient reported chest pain multiple times and had a family history of heart disease. According to the lawsuit, however, he was never referred to a cardiologist.
Most adults know nothing about CKM syndrome—but it impacts nearly everyone
Nearly 90% of adults are believed to already have at least one risk factor of CKM syndrome. The American Heart Association hopes patient education and physician collaborations can help increase awareness about this dangerous condition.
FDA approves oral semaglutide for reducing cardiovascular risks in adults with type 2 diabetes
Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes.
How mental health can influence cardiovascular health
Different subtypes of depression are association with specific cardiometabolic diseases, according to new data out of the Netherlands.
Plant-based diets linked to lower dementia risk for vulnerable heart patients
Adults with a history of CVD, type 2 diabetes and stroke were all associated with a lower dementia risk if they ate a whole food, plant-based diet. The study, published in JACC: Advances, was based on data from more than 71,000 U.K. Biobank participants.

Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes

Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to include a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels.

Acute Coronary Syndromes

Judge files lawsuit over husband’s death—alleges heart symptoms were mismanaged

Most adults know nothing about CKM syndrome—but it impacts nearly everyone

FDA approves oral semaglutide for reducing cardiovascular risks in adults with type 2 diabetes

How mental health can influence cardiovascular health

Plant-based diets linked to lower dementia risk for vulnerable heart patients